Document is current
Any future updates will be listed below
-
Authors
Masarova, Lucia
Qin, Albert
Yoon, Chang Ho
Yacoub, Abdulraheem
Prchal, Josef T.
Mascarenhas, John
- License Information
-
More Information
Article History
Received: 21 December 2025
Accepted: 31 December 2025
First Online: 19 February 2026
Declarations
:
: Not applicable.
: Lucia Masarova: advisory board participation with Cogent, GSK, MorphoSys, and PharmaEssentia. Albert Qin: serves as chief medical officer of PharmaEssentia Corporation. Chang Ho Yoon: serves as a consultant of PharmaEssentia. Abdulraheem Yacoub: consultancy: Incyte, CTI Pharma (SOBI), PharmaEssentia, Pfizer, Novartis, Servier, ABBVIE, Karyopharm Therapeutics, GSK, Blueprint Medicine, Apellis, Gilead, Notable Labs, and Protagonist; Research funding: CTI Pharma (SOBI), Stemline Therapeutics. Josef T. Prchal: AbbVie: Research Funding; PharmaEssentia: Research Funding. John Mascarenhas: Grants (PharmaEssentia, Novartis, Roche, Geron, AbbVie, Kartos, Karyopharm, DISC, SOBI, Italfarmaco Spa); consulting fees (PharmaEssentia, SOBI, Incyte, Roche, Novartis, Merck, Geron, AbbVie, BMS, Galecto, Sumitomo, Italfarmaco Spa, and Takeda); monitoring or advisory board (Incyte, Galecto).
